Physician profile
Xiaomei Chen
NPI 1982767828
$2,816.72
in general payments reported to CMS, 2019-2025
25 companies · $451 in 2025
The $451 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.00 · 2020: $141 · 2021: $446 · 2022: $843 · 2023: $438 · 2024: $419 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $561.24 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $382.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $359.20 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.84 | 2021-2025 | Jardiance |
| Gilead Sciences, INC. | $164.59 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.11 | 2022 | |
| Phathom Pharmaceuticals, INC. | $139.81 | 2024 | Voquezna |
| Pharming Healthcare, INC. | $130.08 | 2024 | Ruconest |
| Corcept Therapeutics | $107.92 | 2023 | Korlym |
| Abbvie INC. | $64.56 | 2021-2023 | Viberzi, Linzess |
| Otsuka America Pharmaceutical, INC. | $57.44 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $56.35 | 2023-2024 | Shingrix, Arexvy |
| Lilly USA, LLC | $56.17 | 2022-2023 | Jardiance |
| Lundbeck LLC | $47.43 | 2025 | Rexulti |
| Stratus Medical, LLC | $41.77 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.52 | 2019-2021 | |
| Alpha Cognition USA, INC. | $35.68 | 2025 | Zunveyl |
| Novartis Pharmaceuticals Corporation | $30.95 | 2021-2023 | |
| Exact Sciences Corporation | $30.74 | 2025 | The Cologuard Plus Collection Kit |
| Ucb, INC. | $24.93 | 2021 | |
| Redhill Biopharma INC. | $23.38 | 2021 | |
| Pfizer INC. | $18.15 | 2024 | |
| Agios Pharmaceuticals, INC. | $15.61 | 2025 | Pyrukynd |
| Genentech USA, INC. | $13.68 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaomei Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.